Bone Care To Announce Second Quarter 2003 Results.

Business Editors/Health & Medical Writers

MIDDLETON, Wis.--(BUSINESS WIRE)--Jan. 10, 2003

Bone Care International, Inc. (Nasdaq:BCII) today announced that it plans to release its second quarter 2003 results after the close of the market on Monday, January 27, 2003. Management will host a conference call on Tuesday, January 28, 2003, at 10:00 a.m. central time. At that time, the Company will also provide an update with regards to the status of the manufacturing of Hectorol(R) Injection. The toll-free number within North America is [phone]; the dial-in number for international participants is [phone]. The call is available for playback until midnight on January 30, 2003 at [phone] within North America and at [phone] for international callers. The playback pass code is 232895. The presentation will be archived for playback at Bone Care's Web site, www.bonecare.com.

About Bone Care International

Bone Care (www.bonecare.com) is a pharmaceutical company engaged in discovering, developing and commercializing improved vitamin D-hormone therapies to treat secondary hyperparathyroidism in patients with kidney, or renal disease, and osteoporosis, and other diseases including psoriasis and cancers of the prostate, breast and colon.

This press release contains forward-looking statements. Statements relating to future net sales, costs of sales, other expenses, profitability, financial resources, or products and production schedules, or statements that predict or indicate future events and trends and which do not relate solely to historical matters identify forward-looking statements. Forward-looking statements are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are based on management's beliefs as well as assumptions made by and information currently available to management. Accordingly, the Company's actual results may differ materially from those expressed or implied in such forward-looking statements due to known and unknown risks and uncertainties that exist in the Company's operations and business environment, including, among other factors, technical risks associated with the development of new products, regulatory policies in the United States and other countries, reimbursement policies of public and private health care payors, introduction and acceptance of new drug therapies, competition from existing products and from new products or technologies, the failure by the Company to produce anticipated cost savings or improve productivity, the timing and magnitude of capital expenditures and acquisitions, currency exchange risks, economic and market conditions in the United States, Europe and the rest of the world, and other risks associated with the Company's operations. The Company disclaims any obligation to update any such factors or to publicly announce any revisions to any of the forward-looking statements contained herein to reflect future events or developments.